AAAAAA

   
Results: 1-18 |
Results: 18
CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity
Authors: Vonderheide, RH Butler, MO Liu, JF Battle, TE Hirano, N Gribben, JG Frank, DA Schultze, JL Nadler, LM
Citation: Rh. Vonderheide et al., CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity, INT J ONCOL, 19(4), 2001, pp. 791-798
Cd40 ligand therapy of lymphoma patients - Reply
Authors: Vonderheide, RH Dutcher, JP Anderson, JE Eckhardt, SG Caron, DA Gribben, JG
Citation: Rh. Vonderheide et al., Cd40 ligand therapy of lymphoma patients - Reply, J CL ONCOL, 19(23), 2001, pp. 4352-4353
Phase I study of recombinant human CD40 ligand in cancer patients
Authors: Vonderheide, RH Dutcher, JP Anderson, JE Eckhardt, SG Stephans, KF Razvillas, B Garl, S Butine, MD Perry, VP Armitage, RJ Ghalie, R Caron, DA Gribben, JG
Citation: Rh. Vonderheide et al., Phase I study of recombinant human CD40 ligand in cancer patients, J CL ONCOL, 19(13), 2001, pp. 3280-3287
Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A0201 restricted epitopes from the human epithelial cell adhesion molecule
Authors: Trojan, A Witzens, M Schultze, JL Vonderheide, RH Harig, S Krackhardt, AM Stahel, RA Gribben, JG
Citation: A. Trojan et al., Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A0201 restricted epitopes from the human epithelial cell adhesion molecule, CANCER RES, 61(12), 2001, pp. 4761-4765
A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2
Authors: Schultze, JL Anderson, KC Gilleece, MH Gribben, JG Nadler, LM
Citation: Jl. Schultze et al., A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2, BR J HAEM, 113(2), 2001, pp. 455-460
Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues
Authors: Harig, S Witzens, M Krackhardt, AM Trojan, A Barrett, P Broderick, R Zauls, AJ Gribben, JG
Citation: S. Harig et al., Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues, BLOOD, 98(10), 2001, pp. 2999-3005
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: Results of a phase II study
Authors: Longo, DL Duffey, PL Gribben, JG Jaffe, ES Curti, BD Gause, BL Janik, JE Braman, VM Esseltine, D Wilson, WH Kaufman, D Wittes, RE Nadler, LM Urba, WJ
Citation: Dl. Longo et al., Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: Results of a phase II study, CANCER J, 6(3), 2000, pp. 146-150
Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma
Authors: Ladetto, M Donovan, JW Harig, S Weller, E Trojan, A Poor, C Schlossman, R Anderson, KC Gribben, JG
Citation: M. Ladetto et al., Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma, BIOL BLOOD, 6(3), 2000, pp. 241-253
Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies
Authors: Trojan, A Schultze, JL Witzens, M Vonderheide, RH Ladetto, M Donovan, JW Gribben, JG
Citation: A. Trojan et al., Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies, NAT MED, 6(6), 2000, pp. 667-672
Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia
Authors: Donovan, JW Ladetto, M Zou, GY Neuberg, D Poor, C Bowers, D Gribben, JG
Citation: Jw. Donovan et al., Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia, BLOOD, 95(8), 2000, pp. 2651-2658
Molecular immunological modulation of target cells to enhance the GVL effect
Authors: Schultze, JL Gribben, JG
Citation: Jl. Schultze et Jg. Gribben, Molecular immunological modulation of target cells to enhance the GVL effect, BAS CLIN ON, 22, 2000, pp. 315-340
A phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma
Authors: Grossbard, ML Multani, PS Freedman, AS O'Day, S Gribben, JG Rhuda, C Neuberg, D Nadler, LM
Citation: Ml. Grossbard et al., A phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma, CLIN CANC R, 5(9), 1999, pp. 2392-2398
Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia
Authors: Schultze, JL Donovan, JW Gribben, JG
Citation: Jl. Schultze et al., Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia, J MOL MED-J, 77(2), 1999, pp. 259-265
Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma
Authors: Friedberg, JW Neuberg, D Stone, RM Alyea, E Jallow, H LaCasce, A Mauch, PM Gribben, JG Ritz, J Nadler, LM Soiffer, RJ Freedman, AS
Citation: Jw. Friedberg et al., Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma, J CL ONCOL, 17(10), 1999, pp. 3128-3135
Bone marrow transplant for lymphoma: where is the field going?
Authors: Gribben, JG
Citation: Jg. Gribben, Bone marrow transplant for lymphoma: where is the field going?, BBA-REV CAN, 1423(3), 1999, pp. C31-C45
Transplantation of anergic histoincompatible bone marrow allografts
Authors: Guinan, EC Boussiotis, VA Neuberg, D Brennan, LL Hirano, N Nadler, LM Gribben, JG
Citation: Ec. Guinan et al., Transplantation of anergic histoincompatible bone marrow allografts, N ENG J MED, 340(22), 1999, pp. 1704-1714
Human non-germinal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: Role of B cells in the maintenance of T cell responses
Authors: Schultze, JL Michalak, S Lowne, J Wong, A Gilleece, MH Gribben, JG Nadler, LM
Citation: Jl. Schultze et al., Human non-germinal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: Role of B cells in the maintenance of T cell responses, J EXP MED, 189(1), 1999, pp. 1-11
Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
Authors: Freedman, AS Neuberg, D Mauch, P Soiffer, RJ Anderson, KC Fisher, DC Schlossman, R Alyea, EP Takvorian, T Jallow, H Kuhlman, C Ritz, J Nader, LM Gribben, JG
Citation: As. Freedman et al., Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma, BLOOD, 94(10), 1999, pp. 3325-3333
Risultati: 1-18 |